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The incursion of ‘‘-omics’’ (e.g. genomics, epi-genomics,
transcriptomics and metabolomics) in epidemiological
studies has revolutionized the practice of epidemiology.
Comprehensive and accurate assessment of environmental
factors and health status has been a perpetual challenge for
epidemiology. Omics are expected to broaden the domain
of exposure assessment and allow more detailed evaluation
of health status, providing further details and additional
platforms of understanding. In recent years, novel -omics
approaches have enabled epidemiologists to quantify
characteristics that were not previously within their reach
and to investigate features that up to a few years ago were
not even in their sight. Moreover, the agnostic approach
that is used in -omics has enabled epidemiology to move
beyond current biological knowledge and contribute to
build upon it. This has provided an unprecedented oppor-
tunity for epidemiology to contribute to cutting-edge and
groundbreaking science by exploring pathways and
mechanisms in more details and advance our understanding
of health determinants at molecular level.
Despite the spectacular promises of -omics that have put
epidemiology in the limelight, addressing the concomitant
criticisms continues to be challenging. Implementing -omics
on a large scale is an expensive effort and thus the investments
are substantial. Stakeholders are eager to see the immediate
clinical or public health applications of the investments.
Nevertheless, current findings are too basic to be immediately
used in practice and efforts for clinical applications are still in
initial phases. Genome-wide association studies (GWAS)
were one of the first –omics technologies that quickly became
popular in epidemiological studies and turned out to be fruitful
in locating potential genes for complex traits and disorders.
Nevertheless, the discoveries have hardly led to a clinically
used drug. Personalized medicine and its successor, precision
medicine, were thought to be fields where GWAS could
contribute in the short term, for example by risk stratification
or individualized treatment based on genetic information.
However, efforts to use GWAS findings in personalized
medicine have not yet been successful due to the small con-
tribution of the identified genetic variants to the risk of dis-
eases. Metabolomics, another -omics that studies the small
molecules, however, appears to be promising and could
potentially tackle these challenges. Metabolites contain more
information on the health status compared to other -omics due
to their closer proximity to the phenotype. Moreover, in
comparison to genetic information that is constant throughout
the life course, the metabolome has the advantage of a
dynamic nature and including real-time information on the
health status.
Metabolomics is either targeted or untargeted. Targeted
metabolomics aims to measure a defined group of chemi-
cally known and biochemically annotated metabolites.
Untargeted metabolomics, however, is a comprehensive
analysis of all quantifiable molecules in a sample including
unknowns chemical. Although targeted metabolomics has
already been used in a number of epidemiological studies,
applying untargeted metabolomics to large-scale epidemi-
ological studies is a relatively novel application for this
technique. Its use, though, is rising due to a combination of
improved laboratory techniques, innovative statistical
methods, and an associated reduction in costs.
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Two of the most commonly used technologies for meta-
bolomics are nuclear magnetic resonance spectroscopy
(NMR) and mass spectrometry (MS). NMR relies on the fact
that certain nuclei (1H, 13C, or 31P) possess the property of
magnetic spin and when placed inside a magnetic field can
adopt different energy levels that can be observed using
radiofrequency waves. MS, however, measures the mass-to-
charge ratio of ions formed from molecules, usually sepa-
rated by chromatography. 1H-NMR spectroscopy has been
widely used in previous studies due to its reproducibility, fast
analysis, continuous performance, and feasibility to study all
organic molecules since they all have protons. However, 1H-
NMR cannot measure metabolites that are present in low
concentrations. Such low concentration metabolites can only
be identified and quantified using more sensitive mass
spectrometry (MS) methods. Despite the fact that NMR has
so far been the dominant technology used in epidemiological
studies, MS may be the main method that will be imple-
mented in epidemiological studies in the future.
In recent years the European Journal of Epidemiology
(EJE) has paid special attention to the flourishing field of ‘‘-
omics epidemiology’’ by publishing papers in this domain
covering topics such as molecular pathology [1], gene-
environment interaction [2], population admixture in
association studies [3], and metabolomics [4]. In this issue
of the EJE Lind and colleagues present a comprehensive
yet uncomplicated and clear overview of MS methods and
their applications in epidemiological studies. The paper
describes technical details of the method, reviews a number
of applications with a focus on epidemiological studies,
goes over key sampling and analytical considerations in
large scale studies, reviews the relevant statistical methods
and highlights major advances in the field.
Many epidemiological studies may currently not see
metabolomics and especially MS as a pressing need.
Nevertheless, the wide range of applications for MS,
ranging from exposure measurements in environmental
epidemiology to risk stratification and etiological research
in classical epidemiology will make the technology
essential in long run. It should be noted that the samples
that will be assayed in future are the ones that are collected
today. The validity of the future quantifications, therefore,
will depend on proper collection, processing and storage of
these samples now. In other words, epidemiologic studies
ought to keep their protocols up-to-date to enhance their
future application in upcoming technologies. In this regard
Lind and colleagues offer a comprehensive description of
sampling for metabolomics studies that could be of interest
to a wide range of epidemiologists currently collecting
population resources even if there is no plan to implement
omics in their studies in the near future.
Implementing metabolomics techniques such as MS
through agnostic approaches calls for collaborative projects
aiming either to extend the discovery by combining several
studies or to seek validity through replication in indepen-
dent samples. Unlike genomics and epigenomics, technical
variability is larger in MS data. Moreover, the assays,
quality control set ups, data preprocessing and metabolite
identification/quantification are not well standardized and
homogenized. The variability produced by these diversities
will lead to major challenges in combining and comparing
the data or translating them from one platform to another
when the assays are done in different centers or in several
batches within the same lab. Papers such as the one by Lind
and colleagues that catalogue a standard practice could be
an initial step towards an urgently needed standardization
of the methods and procedures.
MS is not a novel technique but applying it to epi-
demiological studies is a novel advent. The techniques are
evolving and the field is emerging. It is likely that the
technical challenges that have so far hampered the exten-
sive application of metabolomics and MS techniques at the
population level will be reduced or tackled in the coming
years. Epidemiological resources will provide the infras-
tructure for such a revolution in population-based research
and such a revolution will let the investments that have
made in epidemiological studies flourish once again.
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